Menopur

Menotropin, the active ingredient in Menopur, is a human menopausal gonadotropin presented as an injectable solution for intramuscular or subcutaneous use. It treats infertility due to anovulation, supports ovarian stimulation for assisted reproductive technology, and addresses hypogonadotropic hypogonadism in males.

GNH USA supplies Menopur as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Menotropin (Menopur) is used in reproductive hormone therapy to stimulate gonadal function.

- Anovulatory infertility: promotes follicular development to enable ovulation. - Assisted reproductive technology (IVF): enhances ovarian response to retrieve multiple oocytes. - Male hypogonadotropic hypogonadism: stimulates testicular testosterone production and spermatogenesis.

Menopur may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain or redness. - Abdominal discomfort or bloating. - Headache. - Nausea.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome, potentially severe. - Multiple pregnancy. - Allergic reaction or anaphylaxis. - Thromboembolic events or severe abdominal pain.

When using Menopur, several precautions should be observed to minimize risks.

- Monitor ovarian response: adjust dose based on ultrasound and estradiol levels. - Assess OHSS risk: evaluate patient history and limit stimulation in high‑risk individuals. - Review thyroid function: gonadotropins may affect thyroid hormone metabolism. - Check for allergies: avoid use in patients with known hypersensitivity to menotropin or related proteins. - Use caution in cancer patients: consider potential effects on hormone‑sensitive tumors. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menopur can interact with other medications, influencing its efficacy or safety.

Major Interactions (Avoid): - Concurrent use of other gonadotropins: may cause excessive ovarian response. - High‑dose estrogen therapy: can blunt the intended stimulation effect. - Use with ovarian stimulation protocols that predispose to OHSS: increases severe syndrome risk. - Certain chemotherapy agents: may interfere with hormonal balance.

Moderate Interactions (Monitor Closely): - Corticosteroids: may alter follicular development response. - Anticoagulants: increased bleeding risk if ovarian cysts rupture. - Thyroid hormone replacement: may require dose adjustments. - Antipsychotic medications: potential impact on prolactin levels.